Drug Trial Radar · NCT05446298
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
58
Actual
Start
Dec 22, 2022
Primary completion
Aug 30, 2026
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- OncoC4, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC; GOG Foundation
- First posted
- Jul 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Conditions
- Ovarian Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
Interventions
ONC-392Drug
ONC-392 will be given by IV infusion, q3w.
PembrolizumabDrug
Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 24 months
- Treatment Related Adverse Events (TRAEs) and Immune Related Adverse Events (irAEs)Time frame: 24 months
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Cancer Treatment Centers of America, Phoenix. 403
Goodyear, Arizona
Honor Health, USOR, 406
Phoenix, Arizona
Nuvance Health System, 401
Danbury, Connecticut
Baptist MD Anderson Cancer Center, 404
Jacksonville, Florida
Sudarshan Sharma, MD. LTD. 414
Hinsdale, Illinois
Cancer Treatment Centers of America, Chicago. 410
Zion, Illinois
Northwest Cancer Centers - Dyer, IN - USOR, 422
Dyer, Indiana
Baptist Health Lexington, 407
Lexington, Kentucky
Norton Cancer Institute - St. Matthews, 416
Louisville, Kentucky
Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409
Shreveport, Louisiana
Minnesota Oncology Hematology, P. A. - USOR, 421
Maplewood, Minnesota
Center of Hope, 413
Reno, Nevada
The Valley Hosptial, Inc. 411
Ridgewood, New Jersey
Women's Cancer Care Associates, LLC. 405
Albany, New York
The Ohio State University James Cancer Center, 412
Columbus, Ohio
Oncology Associates of Oregon, P. C. - USOR. 419
Eugene, Oregon
Texas Oncology, P. A. - Austin, USOR. 417
Austin, Texas
Texas Oncology, P.A., Fort Worth - USOR. 420
Fort Worth, Texas
Texas Oncology, P. A. Woodlands - USOR, 418
The Woodlands, Texas
Texas Oncology - Northeast Texas - USOR, 423
Tyler, Texas
Medical College of Wisconsin, 408
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.